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Abstract: Impaired function of regulatory T-cells (Treg) leads to a failure in immune tolerance and triggers
autoimmunity. We analyzed whether the deficiency in Treg in systemic lupus erythematosus (SLE) is accompa-
nied by an increase in effector T-cell responses. We studied the frequencies of IL-17A (Th17) and IFNg (Th1)
producing CD4+ T-cells by flow cytometric detection of intracellular cytokines in PMA/ionomycin stimulated
blood lymphocytes from seven patients with active SLE, eight with SLE in remission, and 11 healthy controls.
Circulating Treg were evaluated as CD4+CD25+ lymphocytes expressing FoxP3. There was no difference in the
percentage of Treg cells between the groups, but their absolute counts were decreased in active SLE (5 [1–7]
cells/μL) compared to inactive SLE (11 [6–15]; p = 0.05) and healthy controls (16 [10–20]; p < 0.01). Both the
frequency and numbers of Th1 cells were decreased in SLE compared to controls. No difference was observed
in the number of Th17 cells, which resulted in a decreased Th1/Th17 ratio. In parallel, a higher Treg/Th17 ratio
in healthy controls (2.2 [1.8–3.6]) compared to active SLE (1.1 [1.0–2.1]; p < 0.05) was observed. There was
a correlation between the number of Treg cells and disease activity status (SLEDAI, r = –0.59). SLE patients in
the active phase of the disease are characterized by a deficiency in Treg cells and decreased Treg/Th17 ratio. This
suggests that the imbalance between major T-cells subsets might be responsible for an increased proinflammato-
ry response in the exacerbation of SLE. (Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 4, pp. 646–653)
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Introduction
Systemic lupus erythematosus (SLE) is a systemic
autoimmune disease characterized by an immune re-
sponse against nuclear antigens, and deposition of
immune complexes in target organs causing inflam-
mation and tissue damage. Failure of T-cell tolerance
towards self-antigens in genetically predisposed indi-
viduals and subsequent production of autoantibod-
ies are the likely factors involved in pathogenesis of
the disease. Controversy still exists regarding the con-
tribution of specific T-helper cell subsets and related
cytokines in the pathogenesis of SLE.
In addition to well characterized Th1 and Th2 lym-
phocytes, naive CD4+ T-cells can also differentiate
towards Th17, a distinct subset of T-helper cells char-
acterized by expression of the transcription factor
RORgt [1]. Th17 cells secrete a profile of potent
proinflammatory cytokines including IL-17A, IL-17F
and IL-22, which act on a variety of cells in resident
tissues and contribute to tissue injury [2]. Recent stud-
ies indicate that Th17 cells, rather than Th1 subset,
are capable of inducing organ-specific autoimmunity
in animal models [3, 4]. Supporting this data, an in-
crease in the fraction of Th17 cells and elevated lev-
els of IL-23 (Th17 differentiation factor) and IL-17
type cytokines have been found in a number of au-
toimmune disorders [5–7].
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The function of self-reacting effector T-cells is
controlled by regulatory T-cells (Treg), yet another
subpopulation of CD4+ lymphocytes which express
transcription factor FoxP3 and participate in main-
taining peripheral tolerance [8]. Though the concept
of the preventive role of Treg cells in autoimmunity is
widely accepted, data regarding SLE is inconsistent
[9]. The studies on circulating Treg cells character-
ized phenotypically indicate either a decrease [10–12],
an increase [13] or no change in their number
[14, 15] compared to healthy controls. A decrease in
Treg numbers or their functional deficiency seem to
be associated with the active stage of the disease [16].
Two recent studies have also shown the Treg to Th17
ratio to be decreased in exacerbated SLE [12, 14].
Considering that lymphopenia is a common clini-
cal finding in lupus patients, it would be interesting
to discover whether a decrease in Treg observed in
active disease is indeed paralleled by an increase in
the number of effector Th1 and Th17 cells.
In this study, we aimed therefore to analyze the
balance between effector and regulatory T-cell sub-
sets in SLE, by studying both the frequencies and
absolute counts of circulating Th1, Th17 and FoxP3+
expressing Treg cells.
Material and methods
Patients and study design. Fifteen patients with SLE (eight
patients in the active phase of the disease and seven in re-
mission) diagnosed according to the American College of
Rheumatology criteria were studied. Activity of the dis-
ease was evaluated using the SLE Disease Activity Index
score (SLEDAI) [17]. Disease exacerbation was defined
as a SLEDAI score ≥ 5. At the time of enrolment, SLE
patients were not being treated with immunosuppressive
drugs, except for glucocorticoids. Clinical and laboratory
characteristics of the SLE patients studied are summarized in
Table 1. Eleven healthy volunteers served as controls. The study
was approved by the Ethics Committee of the Jagiellonian Uni-
versity and informed consent was obtained from all participants.
Isolation of peripheral blood lymphocytes. Peripheral blood
mononuclear cells (PBMC) were isolated from heparinized
peripheral venous blood by Histopaque 1.077 (Sigma-Ald-
rich, St. Louis, MO, USA) gradient centrifugation. PBMC
were resuspended in RPMI-1640 (Sigma-Aldrich) with 10%
human AB serum (ABS, Linz, Austria) and incubated for 30
min at 37°C in a plastic flask to deplete monocytes. Non-ad-
herent PBL (peripheral blood lymphocytes) were cryopre-
served for further experiments completed within one month.
Lymphocyte immunophenotyping. To identify major sub-
populations of T-cells, PBL were triple stained with labeled
monoclonal antibodies (CD45, CD3, CD4, CD8; all from
BD Biosciences) for 30 minutes,  washed in phosphate buff-
ered saline (PBS), and analyzed by flow cytometry (Coulter
EPICS XL, Beckman Coulter, Fullerton, CA, USA). To
identify regulatory T-cells, PBL were labeled with PerCP-
-CD4 and PE-CD25, and then fixed (FACS Lysing Solu-
tion, BD Biosciences), permeabilized (0.2% saponin, Sig-
ma-Aldrich), and intracellularly stained with FITC-anti-
FoxP3 (eBiosciences, San Diego, CA, USA). Treg cells were
recognized as CD4+ cells expressing CD25high and FoxP3+
protein (Figures 1A, B).
Stimulation of peripheral blood lymphocytes and detection of
cytokines. Cryopreserved PBL were thawed, washed in RPMI-
-1640 (10% ABS) and pre-cultured for 2 hours (2 × 106 cells
per well) before stimulation. PBL were then left untreated
(baseline control) or incubated for 5 hours with PMA (final 50
ng/mL; Sigma-Aldrich) and ionomycin (0.7 μg/mL; Sigma-Al-
drich) in the presence of brefeldin-A (10 μg/mL; Sigma-Ald-
rich). Cells were labeled with PerCP-CD4 (BD Biosciences)
for 15 minutes, fixed and permeabilized with Cytofix/Cytop-
erm (BD Biosciences) and stained intracellularly with mono-
clonal antibodies: FITC-IFNg (BD Biosciences) and PE-IL-
-17A (eBiosciences). Samples were washed in Perm/Wash buffer
and analyzed by flow cytometry. Specificity of cytokine stain-
ing was confirmed with appropriate isotype controls. Cytokine
expressing CD4+ cells were classified as Th1 (producing only
IFNg), Th17 (producing IL-17A, but not IFNg) or Th1/17 (pro-
ducing both IL-17A and IFNg). Representative flow cytome-
try dot plots are shown in Figures 1C, D.
Statistical analysis. Statistical analysis was performed us-
ing GraphPad Prism 4.0 (GraphPad Software, Inc., San Di-
ego, CA, USA). All data was presented as medians and IQR
(interquartile range). Differences between two groups were
determined by a Mann–Whitney U or Friedman test. Dif-
ferences between the three groups were analyzed with
ANOVA or Kruskal–Wallis test. Spearman’s rank sum test
was used to analyze correlation coefficients; a p-value < 0.05
was considered significant.
Results
Decrease in absolute count of
regulatory T-cells in active SLE
Total lymphocyte and T-cell (both CD4+ and CD8+)
count was decreased in SLE patients in comparison
with healthy subjects (Table 2). Interestingly, the per-
centage of individual T-cell populations did not dif-
fer between the groups (data not shown). As expect-
ed, the decrease in lymphocyte count was restricted
to SLE patients only during the disease exacerbation
(Figures 2A–C). We found a significantly lower num-
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ber of CD25highFoxP3+ regulatory T-cells in active SLE
compared to the disease remission (p = 0.05) and to
healthy subjects (p < 0.01) (Figure 2D). Interesting-
ly, no difference was observed in the percentage (with-
in CD4+ fraction) of Treg cells (Table 2). Neverthe-
less, individuals characterized by a very low percent-
age of Treg cells (< 1.5% of CD4+) were found only
in the SLE group.
Deficiency in IFNg producing CD4+ T-cells
and decrease in Th1/T17 ratio in SLE
The percentages of individual subpopulations of
CD4+ cells were similar between the groups, with only
a trend (p = 0.1) towards a higher percentage of Th1
cells in the control group (Table 2). When analyzing
the absolute counts of a lineage committed CD4+
cells, we found a significant (p < 0.05) decrease in
the number of Th1 cells both for active and inactive
SLE (Figure 2E). There was no difference in the num-
ber of Th17 cells (Figure 2F). In consequence, Th1/
/Th17 ratio was decreased both in active (22.2 [8.8–
–27.7]) and inactive SLE (19.2 [15.4–23.3]) compared
to controls (29.5 [17.6–38.7]; p < 0.05).
Decreased Treg/Th17 ratio in active SLE
Next we compared the ratios between effector and
regulatory subpopulations of CD4+ cells. We noticed
a considerably higher ratio of Treg to Th17 cells in
healthy controls (2.2 [1.8–3.6]) compared to active (1.1
[1.0–2.1]; p < 0.05) but not inactive SLE (1.5 [1.1–
–2.9]; p = NS). Treg/Th17 ratio did not correlate with
clinical (SLEDAI) or laboratory markers (comple-
ment component C4) of disease activity. In contrast,
the ratio of Th1 to Treg cells did not differ between
the groups (see Table 2).
The number of Treg cells correlate with
markers of disease activity
There was a significant inverse correlation between
SLEDAI score and the serum level of complement
component C4 (Figure 3A) and lymphocyte count
(Figure 3B). We also found a strong positive correla-
tion between the number of Treg cells and the con-
centration of C4 (Figure 3C). Likewise, a significant
negative correlation of Treg count with SLEDAI score
was observed (r = –0.59; p = 0.01). In contrast, the
Table 2. Peripheral blood lymphocyte subpopulations in SLE patients and controls
Unit Healthy subjects (n=11) SLE (n=15)
Lymphocytes Cells/μL 1939 [1591–2059] 1158 [1073–1877]*
CD3+ Cells/μL 1376 [1194–1486] 907 [653–1253]*
CD4+ Cells/μL 673 [556–928] 394 [298–664]§
CD8+ Cells/μL 540 [406–615] 326 [270–492]§
CD4/CD8 Ratio 1.15 [1.09–2.15] 1.20 [0.96–1.45]
Subpopulations of CD4+ lymphocytes (% of CD4+)
Treg % of CD4+ 2.1 [1.9–2.8] 1.8 [0.9–3.0]
Th1 % of CD4+ 25.2 [20.4–35.6] 16.2 [14.6–25.5]§§
Th17 % of CD4+ 0.92 [0.77–1.15] 1.07 [0.65–1.52]
Th1/17 % of CD4+ 0.17 [0.12–0.22] 0.14 [0.06–0.21]
Subpopulations of CD4+ lymphocytes (absolute counts)
Treg Cells/μL 15.7 [10.2–19.7] 7.1 [4.8–12.9]**
Th1 Cells/μL 198 [169–211] 100 [34–139]**
Th17 Cells/μL 6.0 [4.5–9.2] 4.8 [3.7–7.5]
Th1/17 Cells/μL 1.1 [0.78–1.34] 0.7 [0.41–0.95]§
Ratio of particular CD4+ subpopulations
Th1/Th17 Ratio 29.5 [17.6–38.7] 21.6 [13.9–25.0]*
Th1/Treg Ratio 11.3 [8.7–21.7] 13.0 [5.4–19.8]
Treg/Th17 Ratio 2.18 [1.79–3.6] 1.16 [1.06–2.09]**
Abbreviations: SLE — systemic lupus erythematosus; Treg — regulatory T-cells; Th1 — CD4+ cells producing only IFNg;
Th17 — CD4+ cells producing only IL-17; Th1/17 — CD4+ cells producing both IFNg and IL-17
Statistics: Results are presented as medians [IQR]. p-values: **p < 0.01; *p < 0.05; §p = 0.05, §§p = 0.1 compared to healthy controls
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number of Th17 and Th1 cells did not correlate with
SLEDAI or the serum level of C4.
Discussion
The human immune system is equipped with a num-
ber of mechanisms involved in maintaining immune
tolerance and protection against autoimmunity. Treg
lymphocytes are the key cells controlling the autoim-
munization process. Their role is illustrated by an
active and dominant control over the function of ef-
fector T cells. Of these, IL-17A secreting CD4+ cells
have recently been identified as a major subpopula-
tion involved in autoimmune disorders [5].
In patients with active SLE, both the increase in
percentage of circulating Th17 cells, [12, 18, 19] and
elevated serum concentration of IL-17A have been
described [20–24]. However, in some reports, no as-
sociation of IL-17 with clinical markers of disease
activity was found [22, 23]. These inconsistencies are
partly due to enrolment of patients regardless of the
immunosuppressive therapy or at a different phase
of their disease. Indeed, the numbers of Th17 cells in
peripheral blood are usually higher in patients with
renal disease [12].
In the present study, we did not observe any dif-
ferences in the frequency of Th17 cells between SLE
patients and healthy controls. Nevertheless, the per-
centage of Th1 cells, and absolute counts of both Th1
and Treg cells were significantly decreased in the SLE
exacerbation. In consequence, the Th1/Th17 and Treg/
/Th1 ratios were lower in SLE compared to healthy
subjects. We also observed a clear correlation between
the number of Treg cells and markers of disease ac-
tivity (e.g. SLEDAI score and serum C4 concentra-
tion), suggesting their potential role in disease exac-
erbation. The decrease in absolute count of Treg cells
in SLE was also observed by Henriques et al. [25].
Figure 1. Flow cytometry dot-plots showing the gating strategy used in identification of regulatory T-cells and cytokine-
producing CD4+ cells (representative data of a healthy subject). A. IgG2a Isotype control and CD25 staining of CD4+
lymphocytes (gate in inset) in order to identify CD4+CD25high cells within PBL fraction. B. Staining for CD25 and FoxP3 to
distinguish CD25highFoxP3+ regulatory T-cells. C. Isotype control staining of PMA/ionomycin stimulated PBL (gating on
CD4+ cells is shown in inset). D. Staining for IL-17A and IFNg to detect Th1 (expression of IFNg only), Th17 (only
IL17A) and Th1/17 cells (expression of both cytokines)
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Figure 2. Absolute counts of lymphocyte subpopulations in SLE patients (stratified by the activity of the disease) and the
control group: total lymphocytes (A), CD3+ T-cells (B), CD3/CD4+ T-helper cells (C), regulatory T-cells (D), Th1 cells (E)
and Th17 cells (F). Horizontal bars on graphs indicate medians, *p < 0.05, ** p < 0.01
Figure 3. Associations of selected clinical and laboratory parameters in SLE patients (n = 15). A. Correlation of comple-
ment component C4 concentration and SLEDAI score. B. Correlation of SLEDAI score and total lymphocyte count.
C. Correlation of C4 and Treg count
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Additionally, a decrease in the number of circulating
Treg cells is a characteristic feature of active SLE
patients with lymphopenia [26]. Our results suggest
that lymphopenia associated with exacerbation of SLE
may affect primarily Treg and Th1 fractions, but not
Th17, resulting in further dysregulation between the
main effector and regulatory T-cell subsets.
The decrease in Th1 to Th17 ratio in SLE has been
observed by Shah et al. [19], who found an increased
frequency of IL-17A producing CD4+ T-cells in pe-
ripheral blood but no change in Th1 fraction. Also
recently, a considerable increase in Th17 to Treg ra-
tio, which correlated with SLEDAI score, was ob-
served by Xing et al. [12]. Another research group
described an elevated ratio of Th17 to regulatory
T-cells in patients with active SLE, with no evidence
of an increase in the percentage of Th17, pointing to
the imbalance between these subsets as the cause of
disease exacerbation [14]. So it is likely that the dys-
regulation between effector and regulatory T-cells
occurring in lupus could be attributed to immune re-
sistance of self-reacting effector cells to regulatory
lymphocytes, or defective suppressory activity of the
latter. Such mechanisms were initially suggested in
a MRL/lpr mice model of lupus [27] and further con-
firmed in ex vivo studies on human cells [10, 11].
The possible imbalance between Th17 and Treg
cells is supported by molecular studies showing the
presence of reciprocal interaction between these
subpopulations. Though both Th17 and inducible
Treg cells require the same cytokine, TGF-b1, dur-
ing the early stage of differentiation, in the pres-
ence of pro-inflammatory cytokines IL-1b and IL-6,
FoxP3 is down-regulated and T-cells with transition-
al phenotype express a set of proteins essential for
Th17 development (e.g. RORgt and IL-23R) [28].
Additionally, IL-2, which is required for the expan-
sion and maintenance of FoxP3 expressing Treg
cells, has been found to inhibit the development of
Th17 cells [29]. Therefore, the counteractive effects
of IL-2 and IL-6 on the differentiation of Th17 and
Treg in the periphery may hamper immunoregula-
tory responses and facilitate the persistence of au-
toimmune inflammation.
In summary, our data indicates that patients with
active SLE are characterized by a relative deficiency
in Th1 and Treg cells compared to the Th17 subset.
The imbalance between major effector and suppres-
sory subpopulations of CD4+ cells could result in in-
creased proinflammatory response mediated by Th17
cells, and may, at least partially, explain the mecha-
nism operational at disease exacerbation. Addition-
ally, decreased numbers of Treg in the peripheral
blood of lupus patients correlated with clinical and
laboratory markers of disease flare. These results con-
firm earlier reports on the potential use of functional
T-cell phenotyping in the assessment of SLE activity.
Further studies are needed, however, to explain
how Th17/Treg equilibrium translates into a specific
array of lupus symptoms, and whether biological
agents aiming at mediators of Th17 axis may be of
value in SLE therapy.
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